CWBR - CohBar, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6776
-0.0824 (-4.68%)
As of 10:25AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.7600
Open1.9131
Bid1.6000 x 900
Ask1.6800 x 1400
Day's Range1.6000 - 1.9131
52 Week Range1.1100 - 3.8000
Volume37,408
Avg. Volume57,752
Market Cap71.929M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.3160
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CohBar to Present at the 2020 BIO CEO & Investor Conference

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the 2020 BIO CEO & Investor Conference, which is being held February 10-11 at the Marriott Marquis in New York. Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.

  • GlobeNewswire

    CohBar Appoints Jordyn Tarazi as Director of Investor Relations

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, announces the appointment of Jordyn Tarazi as Director of Investor Relations. In this newly created role, Ms. Tarazi is responsible for developing, implementing and leading a strategic global investor relations program for CohBar.

  • GlobeNewswire

    CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 (CXCR4) and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

  • Hedge Funds Have Never Been This Bullish On CohBar, Inc. (CWBR)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On CohBar, Inc. (CWBR)

    We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of CohBar, Inc. (NASDAQ:CWBR) based on that data. […]

  • GlobeNewswire

    CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced new preclinical data confirming the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF). New data show the peptide positively affected all of the efficacy parameters evaluated in the study, including reduction in lung fibrosis, inflammation, and collagen levels after 14 days of administration in a therapeutic mouse model of IPF.

  • GlobeNewswire

    CohBar Reports Third Quarter 2019 Financial Results and Business Update

    MENLO PARK, Calif., Nov. 06, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the completion of the Phase 1a stage of the company’s ongoing Phase 1a/1b study evaluating the safety, tolerability, and activity of CB4211, and the initiation of recruitment for the Phase 1b stage. CB4211 is under development as a potential treatment for nonalcoholic steatohepatitis (NASH) and obesity, and is the first therapeutic candidate based on a mitochondrial-derived peptide to enter clinical testing.

  • GlobeNewswire

    CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced today that the company will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

  • GlobeNewswire

    CohBar Expands Board with Biotech Veteran Misha Petkevich

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, today announced the appointment of Misha Petkevich to its Board of Directors. Mr. Petkevich brings to the company more than three decades of financial and investment experience with life sciences companies in leadership roles at V2M Capital, Robertson Stephens & Co. and Hambrecht & Quist. “Misha’s perspective on the biotech industry and on CohBar is well informed by his decades of financial advisory and investment experience with biotech companies at all stages,” said Albion Fitzgerald, CohBar’s Chairman.

  • GlobeNewswire

    CohBar to Present at the 2019 BIO Investor Forum

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present at the 2019 BIO Investor Forum, which is being held October 22-23 at the Westin St. Francis Hotel in San Francisco, CA. The BIO Investor Forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020.

  • GlobeNewswire

    CohBar Reports Second Quarter 2019 Financial Results and Business Update

    Company to host conference call and webcast today, August 7th, at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage.

  • GlobeNewswire

    CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019.  Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

  • GlobeNewswire

    CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions

    CohBar, Inc. (CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat age-related diseases, today announced its poster presentation is available on the preclinical data on a family of novel peptide analogs related to the mitochondrially encoded peptide CB5064 which are under development as a potential source of treatments for type 2 diabetes, at the American Diabetes Association 79th Scientific Sessions held June 7-11, 2019 in San Francisco, California.

  • GlobeNewswire

    CohBar to Hold 2019 Annual Shareholder Meeting and Investor Update June 18, 2019

    MENLO PARK, Calif., June 05, 2019 -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases.

  • GlobeNewswire

    CohBar to Present Data on Novel Analogs of a Mitochondrially Encoded Peptide with Beneficial Effects in an Animal Model of Type 2 Diabetes at the American Diabetes Association 79th Scientific Sessions

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, today announced that it will present its data on a family of novel analogs of a peptide encoded in mitochondrial DNA showing  beneficial effects on glucose tolerance and weight loss in an animal model of type 2 diabetes. The poster will be presented at the American Diabetes Association, 79th Scientific Sessions at 12:00 PM on June 9, in San Francisco, California.

  • GlobeNewswire

    CohBar Reports First Quarter 2019 Financial Results and Business Update

    MENLO PARK, Calif., May 07, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • ACCESSWIRE

    CohBar, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / CohBar, Inc. (NASDAQ: CWBR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 at 5:00 PM Eastern Time. ...

  • GlobeNewswire

    CohBar Appoints Steven B. Engle as Chief Executive Officer

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, announced today that it has appointed Steven B. Engle as its Chief Executive Officer, effective May 15, 2019. CohBar’s interim Chief Executive Officer Dr. Philippe Calais will continue to serve on the company’s Board, a position he has held since June 2018. “Steven is a highly accomplished healthcare executive, and we are very happy to have him leading the CohBar team at this important time in the company’s evolution,” said Albion J. Fitzgerald, Chairman of the Board of Directors.

  • GlobeNewswire

    CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

    MENLO PARK, Calif., April 26, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar Announces Key Opinion Leader Conference Call and Webcast

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that the Company will host a Key Opinion Leader conference call and webcast on May 2, 2019 featuring thought leaders who will discuss the role of mitochondria in health and aging, and mitochondrial-derived peptides (MDPs) as a novel source of potential therapeutics for a host of major age-related diseases. CohBar's management team will also provide an overview of the company’s mitochondria based therapeutics platform, from identification of peptides encoded within the mitochondrial genome to discovery and development of novel peptide analogs with therapeutic potential, and its lead clinical program targeting NASH and obesity.

  • GlobeNewswire

    CohBar Announces the Appointment of David Greenwood to its Board of Directors

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced the appointment of David Greenwood to its Board of Directors.

  • GlobeNewswire

    CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

    MENLO PARK, Calif., March 18, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.

  • GlobeNewswire

    CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019

    MENLO PARK, Calif., March 04, 2019 -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related.